{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107390","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.446426+00:00","generated_at":"2026-05-16T23:36:13.791772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development","bullets":["Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.","Cash, equivalents & restricted cash $39.8M; plus $36.3M in NIH grant funds; runway into Q2 2027.","Closed $30M registered direct offering of 14.7M shares to institutional investors.","FDA aligned on registrational path for zervimesine (CT1812) in Alzheimer's disease.","Phase 2 START study >75% enrolled; expanded access program for dementia with Lewy bodies ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107390","json":"https://secwatch.observer/filing/0001104659-25-107390.json","markdown":"https://secwatch.observer/filing/0001104659-25-107390.md","text":"https://secwatch.observer/filing/0001104659-25-107390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/0001104659-25-107390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/tm2530237d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:36:13.791772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}